Literature DB >> 187099

Immunotherapy with nonviable microbial components.

E Ribi, K C Milner, D L Granger, M T Kelly, K Yamamoto, W Brehmer, R Parker, R F Smith, S M Strain.   

Abstract

Structural components of microorganisms have been studied for immunopotentiating effect with the aid of transplantable (line 10) tumors in syngeneic guinea pigs. Microbial components were associated with oil droplets, suspended in Tween-saline, and injected intralesionally. BCG cell walls, given in this way, produced regression and cure of 50-60% of established tumors, as did viable BCG. Lipid extraction markedly reduced the tumor-regressing potency of cell walls, but P3, a trehalose mycolate present in the extract, restored full activity to the cell wall residue. P3 alone was nonsensitizing and had no antitumor activity, but it enhanced the latter property of various other microbial products. For example, the cure rates produced by cell walls of M. tuberculosis, M. bovis, M. phlei, or M. smegmatis were enhanced from 20-60% to as much as 90% by addition of P3. P3 also conferred antitumor activity on products from unrelated microbes, such as cell walls of E. coli, and in combination with endotoxins from rough Re mutant salmonellae, it produced cure rates of up to 93%. These results suggest that P3 is essential to the immunopotentiating activity of mycobacteria and that it may be broadly applicable in immunotherapy of cancer with microbial agents.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 187099     DOI: 10.1111/j.1749-6632.1976.tb41700.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

Review 2.  Muramyl peptides. Chemical structure, biological activity and mechanism of action.

Authors:  A Adam; J F Petit; P Lefrancier; E Lederer
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

3.  Failure of C3H mice to develop lung granuloma after intravenous injection of BCG cell wall vaccine. Demonstration of a defect in lymphoid cells.

Authors:  M Kakinuma; K Onoé; M Okada; T Kimura; K Kato; H Okuyama; K Morikawa; K Yamamoto
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

4.  Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.

Authors:  Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Paul M Sondel; Alexander L Rakhmilevich
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

5.  Immunotherapy of guinea pig line 10 hepatoma with nonliving BCG cells in aqueous medium.

Authors:  A Bekierkunst; M B Goren
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

6.  Effects of structural variations in synthetic glycolipids upon mitogenicity for spleen lymphocytes, adjuvancy for humoral immune response and on anti-tumour potential.

Authors:  V N Nigam; J Bonaventure; C Chopra; C A Brailovsky
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

Review 7.  The Interplay between Daptomycin and the Immune System.

Authors:  Theodoros Kelesidis
Journal:  Front Immunol       Date:  2014-02-12       Impact factor: 8.786

8.  Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.

Authors:  Takayuki Yoshino; Jun Miyazaki; Takahiro Kojima; Shuya Kandori; Masanobu Shiga; Takashi Kawahara; Tomokazu Kimura; Takashi Naka; Hideyasu Kiyohara; Miyuki Watanabe; Sho Yamasaki; Hideyuki Akaza; Ikuya Yano; Hiroyuki Nishiyama
Journal:  PLoS One       Date:  2019-01-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.